Back to top

Image: Bigstock

Is GlaxoSmithKline plc (GSK) Outperforming Other Medical Stocks This Year?

Read MoreHide Full Article

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. GlaxoSmithKline plc (GSK - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of GSK and the rest of the Medical group's stocks.

GlaxoSmithKline plc is a member of the Medical sector. This group includes 889 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. GSK is currently sporting a Zacks Rank of #2 (Buy).

Within the past quarter, the Zacks Consensus Estimate for GSK's full-year earnings has moved 2.71% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the latest available data, GSK has gained about 10.36% so far this year. Meanwhile, stocks in the Medical group have lost about 1.65% on average. This means that GlaxoSmithKline plc is performing better than its sector in terms of year-to-date returns.

Breaking things down more, GSK is a member of the Large Cap Pharmaceuticals industry, which includes 14 individual companies and currently sits at #100 in the Zacks Industry Rank. This group has gained an average of 3.36% so far this year, so GSK is performing better in this area.

Going forward, investors interested in Medical stocks should continue to pay close attention to GSK as it looks to continue its solid performance.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


GlaxoSmithKline plc (GSK) - free report >>

Published in